Dukes Iain D. 4

What Happened
Iain D. Dukes, CEO of Traws Pharma, received a grant of 231,336 derivative securities on March 8, 2026. The reported price is $0.00 (total $0 on Form 4) and the award is described in the filing as stock options/awards issued under the company’s 2021 Incentive Compensation Plan.

Key Details

• Transaction date: 2026-03-08; Form 4 filed: 2026-03-10 (filed within the typical 2-business-day window).
• Securities: 231,336 derivative shares (stock option/award) reported at $0.00 per share.
• Vesting: Footnote states the award vests 100% on the first anniversary of the grant date.
• Shares owned after transaction: not specified in the information provided on the Form 4.
• Footnote: Award was approved by the issuer’s compensation committee (comprised of independent directors) under the 2021 Incentive Compensation Plan.

Context
This was a grant/award of derivative securities (not an open-market purchase or sale). Grants to executives are common as compensation and typically vest over time; they do not represent immediate market purchases or sales. Because the grant vests in one year, the CEO must remain employed or meet any plan conditions to realize the shares/options.